Dashboard
Manage Tickers

HUMA


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

btig-maintains-buy-on-humacyte-lowers-price-target-to-6
BTIG Maintains Buy on Humacyte, Lowers Pri...
10/13/2025 12:06:07

BTIG analyst Ryan Zimmerman maintains Humacyte (NASDAQ:HUMA) with a Buy and lowers the price target from $7 to $6.

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
10/07/2025 17:06:17

humacyte-raises-60m-in-oversubscribed-registered-direct-offering-with-institutional-investors-company-has-agreed-to-sell-28436018-shares-of-its-common-stock-and-warrants-to-purchase-28436018-shares-of-common-stock-at-a-combined-price-of-211
Humacyte Raises $60M In Oversubscribed Reg...
10/07/2025 13:05:18

Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineer...

d-boral-capital-maintains-buy-on-humacyte-maintains-25-price-target
D. Boral Capital Maintains Buy on Humacyte...
10/06/2025 18:01:20

D. Boral Capital analyst Jason Kolbert maintains Humacyte (NASDAQ:HUMA) with a Buy and maintains $25 price target.

humacytes-symvess-shows-100-limb-salvage-zero-infections-in-wartime-trauma-patients-in-ukraine-published-in-oxford-academics-military-medicine-journal
Humacyte's Symvess Shows 100% Limb Salvage...
10/06/2025 13:29:48

- Results published in Oxford Academic's Military Medicine Journal -- After up to 18 months of follow-up patients were obse...

Core News & Articles
12 Health Care Stocks Moving In Friday's I...
10/03/2025 17:06:08

d-boral-capital-maintains-buy-on-humacyte-maintains-25-price-target
D. Boral Capital Maintains Buy on Humacyte...
09/30/2025 11:06:16

D. Boral Capital analyst Jason Kolbert maintains Humacyte (NASDAQ:HUMA) with a Buy and maintains $25 price target.

humacyte-secures-us-patent-for-bioengineered-esophagus-composition-using-proprietary-regenerative-tissue-engineering-platform
Humacyte Secures U.S. Patent For Bioengine...
09/29/2025 12:16:30

– Patent covers esophagus produced using Humacyte's proprietary bioengineered regenerative tissue platform, designed for im...

russell-2000-hits-all-time-highs-8-stocks-power-small-cap-comeback
Russell 2000 Hits All-Time Highs: 8 Stocks...
09/18/2025 19:08:11

Small-cap benchmark Russell 2000 ETF hits record high after Fed cuts rates, hinting at more cuts. Small caps rally 43% since ta...

d-boral-capital-maintains-buy-on-humacyte-maintains-25-price-target
D. Boral Capital Maintains Buy on Humacyte...
09/18/2025 11:59:20

D. Boral Capital analyst Jason Kolbert maintains Humacyte (NASDAQ:HUMA) with a Buy and maintains $25 price target.

humacyte-unveils-preclinical-success-of-bioengineered-coronary-vessel-ahead-of-fda-human-trial-plans
Humacyte Unveils Preclinical Success Of Bi...
09/18/2025 11:02:31

Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineer...

humacyte-amends-revenue-interest-deal-with-tpc-makes-50m-repayment-adds-955m-discounted-call-option
Humacyte Amends Revenue Interest Deal With...
09/18/2025 10:25:32

d-boral-capital-maintains-buy-on-humacyte-maintains-25-price-target
D. Boral Capital Maintains Buy on Humacyte...
09/15/2025 13:27:19

D. Boral Capital analyst Jason Kolbert maintains Humacyte (NASDAQ:HUMA) with a Buy and maintains $25 price target.

humacyte-announced-publication-of-outcomes-for-patients-with-hospital-acquired-vascular-complications-treated-with-symvess-in-the-journal-of-vascular-surgery
Humacyte Announced Publication Of Outcomes...
09/15/2025 11:06:14

Results were published in the Journal of Vascular Surgery.Publication described treatment of patients with Symvess who had hosp...

humacyte-inc-files-for-mixed-shelf-of-up-to-350m
Humacyte Inc Files For Mixed Shelf Of Up T...
09/12/2025 21:15:27

-SEC Filing

barclays-initiates-coverage-on-humacyte-with-overweight-rating-announces-price-target-of-35
Barclays Initiates Coverage On Humacyte wi...
08/27/2025 18:18:09

Barclays analyst Matt Miksic initiates coverage on Humacyte (NASDAQ:HUMA) with a Overweight rating and announces Price Targe...

td-cowen-maintains-buy-on-humacyte-lowers-price-target-to-35
TD Cowen Maintains Buy on Humacyte, Lowers...
08/12/2025 15:11:31

TD Cowen analyst Joshua Jennings maintains Humacyte (NASDAQ:HUMA) with a Buy and lowers the price target from $5 to $3.5.

hc-wainwright--co-maintains-buy-on-humacyte-lowers-price-target-to-3
HC Wainwright & Co. Maintains Buy on Humac...
08/12/2025 11:55:05

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Humacyte (NASDAQ:HUMA) with a Buy and lowers the price targ...

Core News & Articles
12 Health Care Stocks Moving In Monday's I...
08/11/2025 17:06:46

d-boral-capital-maintains-buy-on-humacyte-maintains-25-price-target
D. Boral Capital Maintains Buy on Humacyte...
08/11/2025 16:28:48

D. Boral Capital analyst Jason Kolbert maintains Humacyte (NASDAQ:HUMA) with a Buy and maintains $25 price target.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION